Raphael Underwood
Major barriers implementing family involvement for patients with psychosis
84 Responses »
Raphael Underwood summarises a recent systematic review looking at implementing family involvement in the treatment of patients with psychosis.
[read the full story...]Efficacy of high vs. low-potency first-generation antipsychotics for schizophrenia
Laurence Palfreyman summarises 3 recent Cochrane reviews, which investigate high-potency versus low-potency first-generation antipsychotic drugs for schizophrenia. The reviews find little difference in efficacy between the high-potency antipsychotics Trifluoperazine, Haloperidol, Fluphenazine, and low-potency typical antipsychotics.
[read the full story...]Meta-review presents the risks of all-cause and suicide mortality in mental disorders
This recent and well-conducted meta-review concludes that the impact on mortality and suicide of mental disorders is substantial, and probably poorly appreciated as a public health problem. Raphael Underwood’s blog summarises the data for all-cause and suicide mortality in mental disorders.
[read the full story...]Acute and transient psychotic disorders: the ‘third psychosis’ and its relation to schizophrenia
Raphael Underwood reports on routinely collected data from the Scottish Morbidity Record, which suggests that 1 in 8 people with first-ever diagnosed acute and transient psychotic disorders will develop schizophrenia within 3–5 years. Researchers conclude that those at high risk of transition may benefit from monitoring for possible diagnostic change.
[read the full story...]New study demonstrates effectiveness of antipsychotic Pimavanserin for Parkinson’s disease psychosis
When we think of Parkinson’s disease (PD), hallucinations and delusions are probably not the first symptoms that come to mind. And yet, it is estimated that nearly half of all patients with PD experience psychotic symptoms at one time or another. Although deficits in motor function are seen as the hallmark of PD, it is [read the full story…]
